Literature DB >> 31595270

Immunomodulatory effects of tacrolimus (FK506) for the treatment of allergic diseases.

Hemanth Kumar Kandikattu1, Anil Mishra1.   

Abstract

Tacrolimus has been used to prevent allograft rejection and also used in kidney, liver and heart transplantations. Various preclinical and clinical studies demonstrated that Tacrolimus possess immunomodulatory and anti-inflammatory properties. The mechanism of action of Tacrolimus in allergic diseases involves calcineurin inhibition, and downregulation of T-cell reactivity, IgE degranulation, and its actions on mast cells, dendritic cells, basophils, eosinophils and inhibition of transcription of proinflammatory cytokines. Herein we reviewed the Pharmacotherapeutic mechanism of action of Tacrolimus in the prevention of asthma, atopic dermatitis, and allergic conjunctivitis.

Entities:  

Keywords:  FK506; Tacrolimus; allergic conjunctivitis; asthma; atopic dermatitis; calcineurin inhibitor

Year:  2018        PMID： 31595270      PMCID： PMC6783126          DOI： 10.5281/zenodo.2530969

Source DB:  PubMed          Journal:  Int J Cell Biol Physiol


  33 in total

Review 1.  Basophils as T(h)2-inducing antigen-presenting cells.

Authors:  Tomohiro Yoshimoto
Journal:  Int Immunol       Date:  2010-05-25       Impact factor: 4.823

2.  Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506.

Authors:  C A Harrison; R Bastan; M J Peirce; M R Munday; P T Peachell
Journal:  Br J Pharmacol       Date:  2007-01-02       Impact factor: 8.739

3.  RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications.

Authors:  Mayte Suárez-Fariñas; Benjamin Ungar; Joel Correa da Rosa; David A Ewald; Mariya Rozenblit; Juana Gonzalez; Hui Xu; Xiuzhong Zheng; Xiangyu Peng; Yeriel D Estrada; Stacey R Dillon; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2015-03-31       Impact factor: 10.793

Review 4.  Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis.

Authors:  Takeshi Nakahara; Hiroshi Morimoto; Naofumi Murakami; Masutaka Furue
Journal:  Pediatr Allergy Immunol       Date:  2018-01-05       Impact factor: 6.377

5.  Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity.

Authors:  G P Geba; W Ptak; P W Askenase
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

6.  Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation.

Authors:  Guiling Li; Yating Fan; Chao Fan; Xinru Li; Xiaoning Wang; Mei Li; Yan Liu
Journal:  Eur J Pharm Biopharm       Date:  2012-06-15       Impact factor: 5.571

7.  Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin.

Authors:  V L Cohan; B J Undem; C C Fox; N F Adkinson; L M Lichtenstein; R P Schleimer
Journal:  Am Rev Respir Dis       Date:  1989-10

8.  The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases.

Authors:  Hiroshi Fujishima; Naoko Okada; Kenji Matsumoto; Kazumi Fukagawa; Ayako Igarashi; Akio Matsuda; Junya Ono; Shoichiro Ohta; Hideki Mukai; Mamoru Yoshikawa; Kenji Izuhara
Journal:  J Allergy Clin Immunol       Date:  2016-03-07       Impact factor: 10.793

9.  A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.

Authors:  Yuichi Ohashi; Nobuyuki Ebihara; Hiroshi Fujishima; Atsuki Fukushima; Naoki Kumagai; Yayoi Nakagawa; Kenichi Namba; Shigeki Okamoto; Jun Shoji; Etsuko Takamura; Kunihiko Hayashi
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

10.  Tacrolimus reduces urinary excretion of leukotriene E(4) and inhibits aspirin-induced asthma to threshold dose of aspirin.

Authors:  Tetsuya Kawano; Hiroto Matsuse; Yuki Kondo; Ikuko Machida; Sachiko Saeki; Shinya Tomari; Kazuko Mitsuta; Chizu Fukushima; Yasushi Obase; Terufumi Shimoda; Shigeru Kohno
Journal:  J Allergy Clin Immunol       Date:  2004-12       Impact factor: 10.793
View more
  2 in total

1.  Tacrolimus (FK506) treatment protects allergen-, IL-5- and IL-13-induced mucosal eosinophilia.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Alok Kumar Verma; Anil Mishra
Journal:  Immunology       Date:  2021-02-28       Impact factor: 7.215

2.  Characterization and In Vitro and In Vivo Evaluation of Tacrolimus-Loaded Poly(ε-Caprolactone) Nanocapsules for the Management of Atopic Dermatitis.

Authors:  Guilherme Dos Anjos Camargo; Leandro Ferreira; Diego José Schebelski; Amanda Martinez Lyra; Fernanda Malaquias Barboza; Bruna Carletto; Adriana Yuriko Koga; Betina Christi Semianko; Daniele Toniolo Dias; Leandro Cavalcante Lipinski; Andressa Novatski; Vijayasankar Raman; Jane Manfron; Jessica Mendes Nadal; Paulo Vitor Farago
Journal:  Pharmaceutics       Date:  2021-11-26       Impact factor: 6.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.